PerkinElmer Expands Dx Business in China, India with Two Acquisitions | GenomeWeb

NEW YORK (GenomeWeb News) – PerkinElmer has acquired two separate companies, one in China and one in India, in a bid to expand its diagnostics and genetic screening businesses.

The firm said that it has completed its acquisition of SYM-BIO Lifescience, a Shanghai, China-based diagnostics firm for around $63.7 million in cash. SYM-BIO supplied Chinese hospitals with infectious disease diagnostic products. PerkinElmer said that the acquisition doubles its access to hospitals in China, offering the firm a larger base to expand its prenatal and newborn screening business.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: genes involved in histone deacetylation in Arabidopsis, effects of pathogenic presenilin-1 mutations, and more.

After a study finds DNA from antibiotic-resistant bacteria in Beijing smog, residents there worry, according to the New York Times.

Canada begins its search for a chief government science advisor, Nature News reports.

A company is using facial recognition tools to identify genetic disorders from pictures, Technology Review reports.